Hyperion sales and marketing update

Hyperion said Ravicti glycerol phenylbutyrate is available for shipment to patients. In an SEC filing, the company said it expects a full launch this month. Last month, Hyperion said it estimated a mean gross price of $250,000-$290,000 annually per patient for the glycerol phenylbutyrate, a pre-prodrug of phenylacetic acid. FDA approved the drug in February for the management of chronic urea cycle disorders in patients at least two years of age (see BioCentury, Feb. 18). ...